TY - JOUR T1 - Update on Outcome Measure Development in Large-vessel Vasculitis: Report from OMERACT 2018 JF - The Journal of Rheumatology JO - J Rheumatol DO - 10.3899/jrheum.181072 SP - jrheum.181072 AU - Sibel Z. Aydin AU - Joanna C. Robson AU - Antoine G. Sreih AU - Catherine Hill AU - Fatma Alibaz-Oner AU - Sarah Mackie AU - Susan Beard AU - Ahmet Gul AU - Gülen Hatemi AU - Tanaz A. Kermani AU - Alfred Mahr AU - Alexa Meara AU - Nataliya Milman AU - Beverley Shea AU - Gunnar Tómasson AU - Peter Tugwell AU - Haner Direskeneli AU - Peter A. Merkel Y1 - 2019/03/15 UR - http://www.jrheum.org/content/early/2019/05/13/jrheum.181072.abstract N2 - Objective The Outcome Measures in Rheumatology (OMERACT) Vasculitis Working Group seeks to develop validated outcome measures for use in trials for large-vessel vasculitis (LVV). Methods An international Delphi exercise conducted among investigators identified items considered important to measure active disease. In parallel, qualitative research with patients was conducted, including interviews and focus groups. Results Next steps prioritized by the group for LVV include (1) defining disease states (remission, flare, and patient-acceptable symptom state) and (2) selection of patient-reported outcome tools. Conclusion The ultimate goal is to develop an OMERACT-endorsed core set of outcome measures for use in clinical trials of LVV. ER -